Coeptis Therapeutics Holdings, Inc.
COEP
$9.75
$0.272.85%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.11% | -24.52% | -69.30% | -26.92% | -53.05% |
| Depreciation & Amortization | 0.00% | -- | 0.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.89% | -23.25% | -55.31% | 4.56% | 43.34% |
| Operating Income | 72.89% | 23.25% | 55.31% | -4.56% | -43.34% |
| Income Before Tax | 71.20% | 5.22% | 62.28% | -27.61% | -12.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 71.20% | 5.22% | 62.28% | -27.61% | -12.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 71.20% | 5.22% | 62.28% | -27.61% | -12.42% |
| EBIT | 72.89% | 23.25% | 55.31% | -4.56% | -43.34% |
| EBITDA | 75.28% | 24.95% | 57.51% | -4.94% | -45.40% |
| EPS Basic | 80.74% | 44.98% | 78.69% | 31.90% | 43.24% |
| Normalized Basic EPS | 81.13% | 44.98% | 78.69% | 36.65% | 43.24% |
| EPS Diluted | 80.74% | 44.98% | 78.69% | 31.90% | 43.24% |
| Normalized Diluted EPS | 81.13% | 44.98% | 78.69% | 36.65% | 43.24% |
| Average Basic Shares Outstanding | 49.37% | 72.28% | 76.98% | 87.29% | 98.05% |
| Average Diluted Shares Outstanding | 49.37% | 72.28% | 76.98% | 87.29% | 98.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
